Status:
COMPLETED
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
Lead Sponsor:
Faes Farma, S.A.
Conditions:
Seasonal Allergic Rhinitis
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
This is a randomized, double blind, active and placebo controlled, 4 way crossover study in patients with seasonal allergic rhinitis. Patients will receive a single dose of bilastine 20 mg, Cetirizine...
Detailed Description
The objective of the study is to determine the effect of a single dose of bilastine 20 mg on nasal symptoms of allergic rhinitis provoked by spending 4 hours in the Vienna Challenge Chamber . This eff...
Eligibility Criteria
Inclusion
- Have a history of seasonal allergic rhinitis
- Have a positive (as defined in the protocol) skin prick or RAST test within 12 months prior to the screening visit
Exclusion
- Have a clinically significant illness or disease
- Have unstable asthma
- Has participated in a clinical trial 30 days prior to the screening visit
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00420082
Start Date
October 1 2006
End Date
December 1 2006
Last Update
April 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergy Center Vienna West
Vienna, Austria, A-1150